CMC & Manufacturing

Excipient

An inactive substance used as a carrier or vehicle for the active pharmaceutical ingredient in a drug product.

Usage Examples

Magnesium stearate is used as a lubricant excipient.
The formulation uses only compendial excipients.
Excipient compatibility studies showed no interactions.

What is Excipient?

Excipients are inactive ingredients in drug products that serve various functions including bulking agents, binders, disintegrants, lubricants, coatings, preservatives, colors, and flavors. While pharmacologically inactive, excipients significantly impact drug product performance.

Excipient selection affects drug stability, bioavailability, manufacturability, and patient acceptability. Novel excipients require extensive safety data, while compendial excipients (USP-NF, Ph.Eur.) have established safety profiles.

ICH Q8 Pharmaceutical Development describes excipient selection rationale. Each excipient must be controlled by appropriate specifications and tested per approved methods.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 211, ICH Q8, USP NF.

FDAICHHealth Canada

When This Matters

Magnesium stearate is used as a lubricant excipient.
The formulation uses only compendial excipients.
Excipient compatibility studies showed no interactions.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

21 CFR 211ICH Q8USP NF

Frequently Asked Questions

Excipients should be pharmacologically inactive at the dose used, but they can affect drug release, absorption, and stability. Some excipients have safety concerns at high doses or in certain populations.

A novel excipient has no prior approval in a drug product in the relevant region. It requires safety data similar to a new chemical entity to establish its safety profile.